» Articles » PMID: 23179937

High Expression Levels of COX-2 and P300 Are Associated with Unfavorable Survival in Laryngeal Squamous Cell Carcinoma

Overview
Date 2012 Nov 27
PMID 23179937
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

In order to provide a basis for clinical treatment decisions, we explored whether there was a correlation between the expression of COX-2 and P300 and clinical factors in a group of patients with laryngeal squamous cell carcinoma (LSCC). A retrospective analysis of clinicopathological data was conducted in 80 patients with LSCC who presented between January 1997 and December 1998. An immunohistochemistry tissue microarray was conducted of 80 surgically resected LSCC and 20 adjacent normal tissue specimens. Survival analysis and Kaplan-Meier curves were used to compare the effects of clinicopathological factors on survival. The Cox model was applied for multivariate analysis. The expression level of COX-2/P300 in LSCC tissues and adjacent normal tissues were 47.5/50.0 versus 0.0/15.0 %. The expression of COX-2 and P300 was correlated with higher T category, N category, clinical staging, histological grade and recurrence (P < 0.05). P300 expression was correlated with COX-2 expression (P < 0.05). Univariate survival analysis showed that P300, COX-2, N category, clinical staging and recurrence factors were closely correlated with unfavorable survival (P < 0.05). Multivariate analysis showed that COX-2 expression, histological grade and recurrence were independent prognostic factors for LSCC. High expression levels of COX-2 and P300 indicated poor survival outcomes for patients with LSCC.

Citing Articles

Biomarkers in Laryngeal Squamous Cell Carcinoma: The Literature Review.

Verro B, Saraniti C, Carlisi D, Chiesa-Estomba C, Maniaci A, Lechien J Cancers (Basel). 2023; 15(20).

PMID: 37894464 PMC: 10604942. DOI: 10.3390/cancers15205096.


Prognostic and Clinical Significance of COX-2 Overexpression in Laryngeal Cancer: A Meta-Analysis.

Du J, Feng J, Luo D, Peng L Front Oncol. 2022; 12:854946.

PMID: 35530357 PMC: 9074301. DOI: 10.3389/fonc.2022.854946.


Analysis of Chromatin Modifiers and Profiling of Histone Deacetylases (HDAC's) in Human Oral Cancer.

Sajnani A, Shah S, Rashid M, Natu A, Gera P, Gupta S Chonnam Med J. 2021; 57(3):176-184.

PMID: 34621637 PMC: 8485086. DOI: 10.4068/cmj.2021.57.3.176.


A 14-Marker Multiplexed Imaging Panel for Prognostic Biomarkers and Tumor Heterogeneity in Head and Neck Squamous Cell Carcinoma.

Mitsuda J, Tsujikawa T, Yoshimura K, Saburi S, Suetsugu M, Kitamoto K Front Oncol. 2021; 11:713561.

PMID: 34490110 PMC: 8417535. DOI: 10.3389/fonc.2021.713561.


Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex.

Abdullah O, Omran Z, Hosawi S, Hamiche A, Bronner C, Alhosin M Genes (Basel). 2021; 12(5).

PMID: 33922029 PMC: 8143546. DOI: 10.3390/genes12050622.


References
1.
Turnell A, Mymryk J . Roles for the coactivators CBP and p300 and the APC/C E3 ubiquitin ligase in E1A-dependent cell transformation. Br J Cancer. 2006; 95(5):555-60. PMC: 2360682. DOI: 10.1038/sj.bjc.6603304. View

2.
Karamouzis M, Konstantinopoulos P, Papavassiliou A . Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell Res. 2007; 17(4):324-32. DOI: 10.1038/cr.2007.10. View

3.
Li Y, Yang H, Luo R, Zhang Y, Li M, Wang X . High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg. 2011; 91(5):1531-8. DOI: 10.1016/j.athoracsur.2010.12.012. View

4.
Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L . Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res. 2012; 53(1):77-90. DOI: 10.1111/j.1600-079X.2012.00973.x. View

5.
Grudzinski M, Cambruzzi E, Lahude E, Savaris R, Pedrini J, Zettler C . [Cox-2 and CD105 expression in breast cancer and disease-free survival]. Rev Assoc Med Bras (1992). 2006; 52(4):275-80. DOI: 10.1590/s0104-42302006000400031. View